Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Merck KGaA Starts China Trial of Cancer Vaccine

publication date: Dec 11, 2009
Merck KGaA of Germany will conduct a multi-national Phase III clinical trial of the therapeutic cancer vaccine Stimuvax in Asian patients. The trial will enroll 420 patients with advanced non-small cell lung cancer (NSCLC) in five Asian countries: China, Hong Kong, South Korea, Singapore and Taiwan. In its double-blind Phase IIb trial, the addition of Stimuvax to best supporting care extended median survival from 13.3 months to 30.6 months, an excellent result in a particularly difficult form of cancer. More details...

Stock Symbol: (XE: MRK)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here